docetaxel anhydrous has been researched along with proscillaridin in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (proscillaridin) | Trials (proscillaridin) | Recent Studies (post-2010) (proscillaridin) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 123 | 7 | 31 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | proscillaridin (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 2.04 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, WQ; Li, L; Liu, L; Liu, Y; Tong, Y; Wang, F | 1 |
1 other study(ies) available for docetaxel anhydrous and proscillaridin
| Article | Year |
|---|---|
Proscillaridin A slows the prostate cancer progression through triggering the activation of endoplasmic reticulum stress.
Topics: Androgens; Animals; Apoptosis; Cell Movement; Disease Progression; Docetaxel; Endoplasmic Reticulum Stress; Humans; Male; Mice; Neoplasm Metastasis; Proscillaridin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2020 |